Table 1.

LME analysis of pupil dilation and skin conductance during fear acquisition and re-learning, as well as startle eye-blink responses and pupil dilation during recall. Significant effects are marked with “*”

Fear acquisition	Pupil dilation				Skin Conductance
Effect	F-value	df		p-value	F-value	df		p-value
Drug (doxycycline/placebo)	0.10	1,	6346	0.75	0.00	1,	6681	0.98
Trial number	171.02	1,	6346	< .001*	543.77	1,	6681	< .001*
Condition (CS + /CS-1,2,3,4)	65.67	4,	6346	< .001*	19.59	4,	6681	< .001*
Drug x Trial	0.03	1,	6346	0.86	4.78	1,	6681	0.029*
Drug x Condition	2.63	4,	6346	0.033*	0.09	4,	6681	0.99
Trial x Condition	1.06	4,	6346	0.37	2.74	4,	6681	0.027*
Drug x Trial x Condition	1.62	4,	6346	0.17	0.53	4,	6681	0.71
Fear recall	Startle Eye-blink				Pupil dilation
Effect	F-value	df		p-value	F-value	df		p-value
Drug (doxycycline/placebo)	0.55	1,	8507	0.46	1.58	1,	8507	0.201
Trial number	1996.41	1,	8507	< .001*	158.64	1,	8507	< .001*
Condition (CS + /CS-1,2,3,4)	101.56	4,	8507	< .001*	57.00	4,	8507	< .001*
Drug x Trial	0.08	1,	8507	0.78	2.91	1,	8507	0.09
Drug x Condition	1.56	4,	8507	0.18	0.66	4,	8507	0.62
Trial x Condition	6.64	4,	8507	< .001*	14.51	4,	8507	< .001*
Drug x Trial x Condition	2.57	4,	8507	0.036*	0.29	4,	8507	0.89
Fear re-learning	Pupil dilation				Skin Conductance
Effect	F-value	df		p-value	F-value	df		p-value
Drug (doxycycline/placebo)	1.10	1,	2984	0.30	0.60	1,	3182	0.44
Trial number	13.54	1,	2984	< .001*	244.93	1,	3182	< .001*
Condition (CS + /CS-1,2,3,4)	62.33	4,	2984	< .001*	21.13	4,	3182	< .001*
Drug x Trial	3.50	1,	2984	0.062	16.31	1,	3182	< .001*
Drug x Condition	0.31	4,	2984	0.87	2.39	4,	3182	0.048*
Trial x Condition	2.44	4,	2984	0.045*	6.36	4,	3182	< .001*
Drug x Trial x Condition	0.31	4,	2984	0.87	1.03	4,	3182	0.39